|
|
|
|
Office Locations:
|
50 Binney Street
Cambridge, MA 02142
Phone: 617-252-7500
Fax: 617-252-7600
| |
|
|
|
|
|
Life Sciences & Healthcare
Medical Device
|
|
|
Sanofi Ventures is the corporate venture capital arm of Sanofi. Previously known as Sanofi-Genzyme BioVentures, the firm offers its portfolio companies access to Sanofi's established expertise and capabilities in science, preclinical and clinical development, regulatory, manufacturing, market access, commercialization, and more. Sanofi invests in early-stage companies developing transformative technologies and products that are considered too early for business development. Sanofi Ventures invests directly in private early-stage biotech and digital health companies with transformative new products and technologies that align with Sanofi's strategy. Current core areas of strategic interest include: rare diseases; vaccines; breakthrough therapies in other core areas of interest: immunology, neurology, oncology, diabetes, and cardiovascular disease; and digital health.
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
|
| Name | |
| |
Title | |
Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
|
| Christopher Gagliardi | |
| |
Director of Investments | |
| Cris De Luca | |
| |
Global Head of Digital Investments | |
| Daniel Mansuri | |
| |
Associate Director | |
| Jason Hafler | |
| |
Managing Director | |
| Laia Crespo | |
| |
EU Head of Investments | |
|
|
|
Date
|
Name
|
State
|
Amount
|
Stage
|
06/22/2026
|
Nura Bio
|
CA
|
$73,800,000
|
Series B
|
05/13/2026
|
BranchLab
|
CO
|
$26,000,000
|
Series A
|
03/20/2026
|
Earendil Labs
|
DE
|
$787,000,000
|
|
02/18/2026
|
Korsana Biosciences
|
MA
|
$175,000,000
|
Seed and Series A
|
01/12/2026
|
Diagonal Therapeutics
|
MA
|
$125,000,000
|
Series B
|
11/18/2025
|
Lifordi Immunotherapeutics
|
MA
|
undisclosed
|
Strategic
|
10/09/2025
|
Expedition Therapeutics
|
CA
|
$165,000,000
|
Series A
|
10/02/2025
|
Star Therapeutics
|
CA
|
$125,000,000
|
Series D
|
09/17/2025
|
Character Biosciences
|
NJ
|
$17,000,000
|
Series B Extension
|
|
|
|
|
|
|
|
